Post by pdidit on Jul 17, 2011 8:33:17 GMT -5
I am posting this in case some of you missed the opportunity to listen in on the important radio announcement with Dr. Fry of Fry Laboratories, who has been studying biofilm. I think it is a breakthrough for all of us...or at the very at least, those of us who are quite ill and not seeing results from all our efforts to beat down this disease.
I believe in the fungal theory of possibly attracting insects too, so this all peaked my interest. I ordered the blood test through my lyme physician and sure enough, it came back positive for biofilm in my blood and the protozoa. This test further confirmed my positive metametrix comprehensive stool analysis back in 2008 that came back positive for an unknown protozoa and yeast--yet they had not come up with any protocol at the time, nor did they know of morgellons, so was advised to just take a round of Alinia --a broad spectrum antiparasitic drug. Side effects were few with the exception of bruising...my doctor, not being a parasitologist, felt uncomfortable to prescribe this for me again with this kind of bruising.
If you are interested, again, here is the radio link in case you want to listen in to Dr. Fry explaining some of his findings, and following are links to info you might be interested in, if you are so inclined to follow up and order these tests [you need a local doctor on board to order the tests for you]:
www.blogtalkradio.com/pamcrane/2011/05/19/1-step-blood-test-discovers-protozoa-under-biofilm-structure?sms_ss=email&at_xt=4dd6203db4259bdf,0
Thu, May 19, 2011 4:00PM Pacific
Fry Labs discusses Protozoa
1 Step Blood Test Discovers Protozoa
Under Biofilm Structure
Here is an explanation from the Fry labs online site:
Biofilms [best described as a slime matrix] are considered the rule in nature rather than the exception. If you have chronic infection, biofilms may be an underlying cause. Many, if not most, microorganisms form and persist in cohesive community structures termed biofilms. These cells secrete a gelatinous intracellular substance consisting of an extracellular polysaccharide (sugar), DNA, and protein matrix. Biofilms are often found attached to living and inert stable surfaces that have a constant liquid flow that brings nutrients and removes waste products from the biofilms. Biofilms often are not composed of a single organism but contain two or more organisms making significant contributions to the biological stability, characteristics, and behavior of the resulting biofilm. Organisms found within biofilms have distinct genetic expression and functional behavior compared to individual organisms subsisting in an individual planktonic state. The establishment and life cycle of biofims on surfaces typically proceed through four main stages: 1) Initial Attachment, 2) Irreversible Attachment, 3) Various Maturation Phases, 4) Active Dispersion or Blebbing/Fragmenting. Many microorganisms spend most of their life cycle in a persistent biofilm state switching to free-living or planktonic phases only during brief periods when environmental conditions are favorable. As Dr. Bill Costerton, the dean of Biofilms succinctly says in his text, biofilms are “- a structured community of bacterial cells enclosed in a self-produced polymer matrix and attached to an inert or living surface.”[1].
Biofilms are observed on most stable non-sterile surfaces in an aquatic environment. Biofilms are found in natural environments such as hot springs, rivers and streams, lakes, subterranean stromatolites, and tide pools, to man-made and industrial environments such as water and drainage pipes, sanitation systems, house-hold sinks, toilets, and showers, and even in the water tanks of nuclear power plants. Lastly, biofilms are ubiquitous and present in normal and diseased states in humans. It is estimated that 80% of all human infections have biofilm involvement. These infections range from urinary tract infections, middle-ear infections, cystic fibrosis, dental plaque, chronic skin infections, many chronic diseases, and coatings on indwelling devices such as joint replacement, catheters, cardiac valves, and contact lenses [1-15].
Dental Health
The involvement of biofilms in the dental industry has long been studied and recognized as important in improving dental health. The dental films and plaque are primarily polymicrobial biofilms. Typically these biofilms consist of bacteria that are considered normal oral flora and usually are kept in balance by normal dental hygiene and the other cohabitating bacteria, however the population dynamics and members of these biofilms may change and induce conditions where tooth decay, gingivitis, and other oral health problems may arise. Where dental health is concerned, it is synonymous with biofilms.
Chronic Wounds
Another important impact of biofilms in human health is cutaneous and skin related biofilm infections. Many infections are easily treated with antibiotics or resolve spontaneously through the body’s natural immune response, however biofilms complicate this picture. When certain species of bacteria and/or fungi are present, they may produce a biofilm-based infection that is exceptionally difficult to treat. These chronic wounds are typified by open wounds that fail to heal, are recalcitrant to antibiotic treatment, produce a profuse seepage, and represent a legitimate risk to patient health. All too often, invasive biofilm-based infections result in the removal of the afflicted area or limb! Recent advances in treatments for biofilm-based chronic wounds include multi-drug therapies, rotational strategies, routine cleaning, and direct topical application of antibiofilm agents.
Chronic Sinus and Inner Ear Infections
One additional recognized involvement of biofilms in human health is its role in chronic rhinosinusitis (sinus infections) and otitis media (inner ear infections). In both cases the symptoms may be due to a persistent biofilm-based infection that the body fails to fully eliminate. Continual aggravation by these infections may produce lasting, disrupting, and damaging effects. Treatment options informed by biofilm research for ear, nose, and throat (ENT) are currently an area of great interest and it is likely future treatments will be guided by this emerging information.
Biofilm Research
Fry Laboratories couples our clinical diagnostics with a robust research and development lab charged with the singular task to investigate novel infections, develop cutting edge and valuable assays, and execute basic science research with the explicit task to inform and assist in patient treatment. Our involvement with biofilms started in the Fall of 2008 when we were researching techniques to improve the existing detection methods for Bartonella and other epierythrozoan bacterial species in the blood of afflicted patients. Simply, we observed hematologic biofilm forming processes and neutrophil extracellular traps (NETs) in patients with chronic infections and illness [16-32]. Our laboratory is one of the first to report biofilm forming protozoan communities [33]. This ultimately resulted in the refinement of the Advanced Stains test that places the power of a generalized morphological screening test in the hands of physicians and health care professionals. Now intense research is focused on the nature, contribution, and involvement of blood-borne biofilm infections. Fry Laboratories has made great strides in the molecular identification of the organisms involved, testing, treatment options, and understanding the contributions of biofilms make to some of the most intractable health concerns currently faced.
www.frylabs.com/biofilm.php
And here are further explanations of what Dr. Fry is finding:
publichealthalert.org/Articles/marybudinger/biofilm.htm
Dr. Fry calls this new strain of protozoa FL1953 :
Dr. Stephen Fry on FL1953 / Protomyxozoa rheumatica
Dr. Fry is doing some exciting work on a new biofilm-forming protozoan previously referred to as FL1953 and only recently renamed to Protomyxozoa rheumatica, a highly immunosuppressive microorganism. He refers to it as the premier pathogen.
I recently had the opportunity to attend a lecture by Dr. Stephen Fry MD as part of Dr. Klinghardt's recent "Beyond Lyme" conference. I'm still working on my notes from that event and will post them soon. In the meantime, I just listened to a radio interview from Dr. Fry which can be found here.
Some of the key points from the the radio interview:
FL1953 is a new, unique protozoan organism that is found in people with CFS, Fibromyalgia, Multiple Sclerosis, ALS, and Rheumatoid Arthritis.
People with Morgellon's also have evidence of the organism. In Morgellon's, Dr. Fry talked about this new protozoan possibly suppressing the immune system such that a fungal/mycelial condition then develops leading to the symptoms of Morgellons.
Dr. Fry discussed the use of Tetracyclines, Zithromax, Plaquenil and other options, but more interesting were his other recommendations. One of the future projects his lab is working on is to complete sensitivity testing of various therapies for this new protozoan.
He shared that diet is very important. The protozoan loves lipids (fats) and that lipid restriction via low-fat diets has been a very powerful tool. Lipids and fatty acids also play a role in the formation of biofilms which seem to collapse with lipid restriction.
He discussed the benefits of a whole food, plant-based diet full of bioflavanoids; which themselves act as an antibiotic.
He suggested that many people with chronic illness may struggle with wheat not due to the gluten content but due to the high arginine which the FL1953 protozoan thrives on.
Many of these concepts are still emerging, but it appears that Dr. Fry's protozoan may be an important piece of the puzzle. I recently had blood drawn to test for this organism and biofilms with Dr. Fry's lab and will post a blog about my results on my site when they are available. For information on tests available from Fry Labs, visit their web site.
www.betterhealthguy.com/joomla/blog/243-dr-stephen-fry-on-fl1953
Hope this gives us another piece of the puzzle!
Love
Pdidit
I believe in the fungal theory of possibly attracting insects too, so this all peaked my interest. I ordered the blood test through my lyme physician and sure enough, it came back positive for biofilm in my blood and the protozoa. This test further confirmed my positive metametrix comprehensive stool analysis back in 2008 that came back positive for an unknown protozoa and yeast--yet they had not come up with any protocol at the time, nor did they know of morgellons, so was advised to just take a round of Alinia --a broad spectrum antiparasitic drug. Side effects were few with the exception of bruising...my doctor, not being a parasitologist, felt uncomfortable to prescribe this for me again with this kind of bruising.
If you are interested, again, here is the radio link in case you want to listen in to Dr. Fry explaining some of his findings, and following are links to info you might be interested in, if you are so inclined to follow up and order these tests [you need a local doctor on board to order the tests for you]:
www.blogtalkradio.com/pamcrane/2011/05/19/1-step-blood-test-discovers-protozoa-under-biofilm-structure?sms_ss=email&at_xt=4dd6203db4259bdf,0
Thu, May 19, 2011 4:00PM Pacific
Fry Labs discusses Protozoa
1 Step Blood Test Discovers Protozoa
Under Biofilm Structure
Here is an explanation from the Fry labs online site:
Biofilms [best described as a slime matrix] are considered the rule in nature rather than the exception. If you have chronic infection, biofilms may be an underlying cause. Many, if not most, microorganisms form and persist in cohesive community structures termed biofilms. These cells secrete a gelatinous intracellular substance consisting of an extracellular polysaccharide (sugar), DNA, and protein matrix. Biofilms are often found attached to living and inert stable surfaces that have a constant liquid flow that brings nutrients and removes waste products from the biofilms. Biofilms often are not composed of a single organism but contain two or more organisms making significant contributions to the biological stability, characteristics, and behavior of the resulting biofilm. Organisms found within biofilms have distinct genetic expression and functional behavior compared to individual organisms subsisting in an individual planktonic state. The establishment and life cycle of biofims on surfaces typically proceed through four main stages: 1) Initial Attachment, 2) Irreversible Attachment, 3) Various Maturation Phases, 4) Active Dispersion or Blebbing/Fragmenting. Many microorganisms spend most of their life cycle in a persistent biofilm state switching to free-living or planktonic phases only during brief periods when environmental conditions are favorable. As Dr. Bill Costerton, the dean of Biofilms succinctly says in his text, biofilms are “- a structured community of bacterial cells enclosed in a self-produced polymer matrix and attached to an inert or living surface.”[1].
Biofilms are observed on most stable non-sterile surfaces in an aquatic environment. Biofilms are found in natural environments such as hot springs, rivers and streams, lakes, subterranean stromatolites, and tide pools, to man-made and industrial environments such as water and drainage pipes, sanitation systems, house-hold sinks, toilets, and showers, and even in the water tanks of nuclear power plants. Lastly, biofilms are ubiquitous and present in normal and diseased states in humans. It is estimated that 80% of all human infections have biofilm involvement. These infections range from urinary tract infections, middle-ear infections, cystic fibrosis, dental plaque, chronic skin infections, many chronic diseases, and coatings on indwelling devices such as joint replacement, catheters, cardiac valves, and contact lenses [1-15].
Dental Health
The involvement of biofilms in the dental industry has long been studied and recognized as important in improving dental health. The dental films and plaque are primarily polymicrobial biofilms. Typically these biofilms consist of bacteria that are considered normal oral flora and usually are kept in balance by normal dental hygiene and the other cohabitating bacteria, however the population dynamics and members of these biofilms may change and induce conditions where tooth decay, gingivitis, and other oral health problems may arise. Where dental health is concerned, it is synonymous with biofilms.
Chronic Wounds
Another important impact of biofilms in human health is cutaneous and skin related biofilm infections. Many infections are easily treated with antibiotics or resolve spontaneously through the body’s natural immune response, however biofilms complicate this picture. When certain species of bacteria and/or fungi are present, they may produce a biofilm-based infection that is exceptionally difficult to treat. These chronic wounds are typified by open wounds that fail to heal, are recalcitrant to antibiotic treatment, produce a profuse seepage, and represent a legitimate risk to patient health. All too often, invasive biofilm-based infections result in the removal of the afflicted area or limb! Recent advances in treatments for biofilm-based chronic wounds include multi-drug therapies, rotational strategies, routine cleaning, and direct topical application of antibiofilm agents.
Chronic Sinus and Inner Ear Infections
One additional recognized involvement of biofilms in human health is its role in chronic rhinosinusitis (sinus infections) and otitis media (inner ear infections). In both cases the symptoms may be due to a persistent biofilm-based infection that the body fails to fully eliminate. Continual aggravation by these infections may produce lasting, disrupting, and damaging effects. Treatment options informed by biofilm research for ear, nose, and throat (ENT) are currently an area of great interest and it is likely future treatments will be guided by this emerging information.
Biofilm Research
Fry Laboratories couples our clinical diagnostics with a robust research and development lab charged with the singular task to investigate novel infections, develop cutting edge and valuable assays, and execute basic science research with the explicit task to inform and assist in patient treatment. Our involvement with biofilms started in the Fall of 2008 when we were researching techniques to improve the existing detection methods for Bartonella and other epierythrozoan bacterial species in the blood of afflicted patients. Simply, we observed hematologic biofilm forming processes and neutrophil extracellular traps (NETs) in patients with chronic infections and illness [16-32]. Our laboratory is one of the first to report biofilm forming protozoan communities [33]. This ultimately resulted in the refinement of the Advanced Stains test that places the power of a generalized morphological screening test in the hands of physicians and health care professionals. Now intense research is focused on the nature, contribution, and involvement of blood-borne biofilm infections. Fry Laboratories has made great strides in the molecular identification of the organisms involved, testing, treatment options, and understanding the contributions of biofilms make to some of the most intractable health concerns currently faced.
www.frylabs.com/biofilm.php
And here are further explanations of what Dr. Fry is finding:
publichealthalert.org/Articles/marybudinger/biofilm.htm
Dr. Fry calls this new strain of protozoa FL1953 :
Dr. Stephen Fry on FL1953 / Protomyxozoa rheumatica
Dr. Fry is doing some exciting work on a new biofilm-forming protozoan previously referred to as FL1953 and only recently renamed to Protomyxozoa rheumatica, a highly immunosuppressive microorganism. He refers to it as the premier pathogen.
I recently had the opportunity to attend a lecture by Dr. Stephen Fry MD as part of Dr. Klinghardt's recent "Beyond Lyme" conference. I'm still working on my notes from that event and will post them soon. In the meantime, I just listened to a radio interview from Dr. Fry which can be found here.
Some of the key points from the the radio interview:
FL1953 is a new, unique protozoan organism that is found in people with CFS, Fibromyalgia, Multiple Sclerosis, ALS, and Rheumatoid Arthritis.
People with Morgellon's also have evidence of the organism. In Morgellon's, Dr. Fry talked about this new protozoan possibly suppressing the immune system such that a fungal/mycelial condition then develops leading to the symptoms of Morgellons.
Dr. Fry discussed the use of Tetracyclines, Zithromax, Plaquenil and other options, but more interesting were his other recommendations. One of the future projects his lab is working on is to complete sensitivity testing of various therapies for this new protozoan.
He shared that diet is very important. The protozoan loves lipids (fats) and that lipid restriction via low-fat diets has been a very powerful tool. Lipids and fatty acids also play a role in the formation of biofilms which seem to collapse with lipid restriction.
He discussed the benefits of a whole food, plant-based diet full of bioflavanoids; which themselves act as an antibiotic.
He suggested that many people with chronic illness may struggle with wheat not due to the gluten content but due to the high arginine which the FL1953 protozoan thrives on.
Many of these concepts are still emerging, but it appears that Dr. Fry's protozoan may be an important piece of the puzzle. I recently had blood drawn to test for this organism and biofilms with Dr. Fry's lab and will post a blog about my results on my site when they are available. For information on tests available from Fry Labs, visit their web site.
www.betterhealthguy.com/joomla/blog/243-dr-stephen-fry-on-fl1953
Hope this gives us another piece of the puzzle!
Love
Pdidit